Considering the glucose- and insulin-lowering actions of FGF19 and/or FGF21 in diabetic rodents, the potential of FGF19 and/or FGF21 treatment to ameliorate impaired glucose tolerance and insulin resistance in GDM patients warrants future attention. The gene discussed is INS; the disease is Impaired glucose tolerance.